Genmab | GEN - Operating Profit


Genmab reported DKK260M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Almirall EUR 71.55M 41.32M Jun/2026
Amarin USD -2.26M 564K Dec/2025
Amgen USD 4.61B 777M Jun/2026
argenx SE USD 493M 99M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bayer EUR 3.53B 2.42B Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Demant DKK 2.09B 224M Dec/2025
Exelixis USD 251.34M 15.43M Mar/2026
Fresenius Medical Care EUR 268M 395M Mar/2026
Genmab DKK 260M 199M Dec/2025
GlaxoSmithKline GBP 2.6B 312M Jun/2026
GN Store Nord DKK -68M 638M Mar/2026
GRIFOLS EUR 329M 80M Jun/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Insmed USD -200.28M 49.43M Mar/2026
Lakefront Biotherapeutics EUR -63.7M 844.26M Mar/2026
Lonza CHF 673M 243M Jun/2025
Merck EUR 1.05B 572M Mar/2026
Novartis USD 4.75B 515M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 2.38B 449M Jun/2026
UCB EUR 1.29B 571M Dec/2025